SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

December 03, 2014 16:00 ET

Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014

TUSTIN, CA--(Marketwired - Dec 3, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time (4:30 PM Eastern Standard Time). Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.

To listen to the live webcast, or access the archived webcast, please visit:

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immuno-oncology candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at

Contact Information